Skip to main content
NCBI home page
Current Therapeutic Research, Clinical and Experimental logoLink to Current Therapeutic Research, Clinical and Experimental
. 2008 Oct;69(5):412–422. doi: 10.1016/j.curtheres.2008.10.002

Effects of amlodipine and candesartan on arterial stiffness estimated by cardio-ankle vascular index in patients with essential hypertension: A 24-week study

Mie Kurata 1, Takafumi Okura 1,a, Sanae Watanabe 1, Jun Irita 1, Daijiro Enomoto 1, Masanori Johtoku 1, Ken-ichi Miyoshi 1, Mitsuko Koresawa 1, Tomikazu Fukuoka 1, Jitsuo Higaki 1
PMCID: PMC3969957  PMID: 24692816

Abstract

Background: Aortic stiffness assessed by brachio-ankle pulse wave velocity (baPWV) can be used to predict cardiovascular events. However, baPWV is dependent on blood pressure. Antihypertensive drugs have been reported to reduce baPWV; but it is difficult to determine if this effect is associated with lowered blood pressure or reduced arterial stiffness.

Objectives: The primary end point of this study was to assess whether antihypertensive drugs reduce arterial stiffness as estimated by cardio-ankle vascular index (CAVI). The secondary end point was to compare the effects of 2 widely used drugs, the calcium-channel blocker amlodipine and the angiotensin II receptor blocker candesartan, on arterial stiffness.

Methods: Between October 2005 and September 2006, consecutive Japanese outpatients with essential hypertension (EHT) (defined as using antihypertensive drugs at screening, systolic blood pressure [SBP] > 140 mm Hg, or diastolic BP [DBP] >90 mm Hg) were assigned to treatment for 24 weeks with either amlodipine (5–10 mg/d) or candesartan (8–12 mg/d). Arterial stiffness was evaluated with CAVI before and after 24 weeks of treatment. Relative change in arterial stiffness from baseline was also compared. The evaluator was blinded to treatment.

Results: Twenty patients (11 men, 9 women; mean [SD] age, 62 [10] years) were included in the study. There were no significant differences in clinical characteristics between the 2 groups. At baseline, mean (SD) CAVI was not significantly different in the amlodipine group compared with the candesartan group (8.93 [0.93] vs 8.46 [1.34], respectively). During the 24-week treatment period, mean SBP and DBP decreased significantly in both the amlodipine (14/10 mm Hg; P = 0.006 and P = 0.005) and the candesartan groups (13/11 mm Hg; P = 0.033 and P = 0.005). Amlodipine was associated with a significant change in CAVI from baseline (8.93 [0.93] vs 8.60 [1.50]; P = 0.017), whereas candesartan was not (8.46 [1.34] vs 8.81 [1.20]). The percentage change in CAVI was significantly different in the amlodipine group compared with the candesartan group (−7.14 [8.83] vs 5.85 [16.0], respectively; P = 0.038). After 24 weeks of treatment, the CAVI of the amlodipine group was still numerically larger than baseline CAVI of the candesartan group, although the difference was not statistically significant. Furthermore, there was no significant difference in absolute CAVI between the 2 groups after 24 weeks, but the relative change from baseline was significant in favor of amlodipine. Logistic regression analysis revealed that amlodipine improved CAVI independent of its antihypertensive effect.

Conclusion: These data suggest that amlodipine and candesartan had different effects on aortic stiffness estimated by CAVI, despite similar effects on brachial blood pressure after 24 weeks of treatment in these Japanese patients with EHT.

Key Words: arterial stiffness, amlodipne, candesartan, cardio-ankle vascular index

Full Text

The Full Text of this article is available as a PDF (668.7 KB).

References

  • 1.Blacher J, Asmar R, Djane S. Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients. Hypertension. 1999;33:1111–1117. doi: 10.1161/01.hyp.33.5.1111. [DOI] [PubMed] [Google Scholar]
  • 2.Laurent S, Boutouyrie P, Asmar R. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension. 2001;37:1236–1241. doi: 10.1161/01.hyp.37.5.1236. [DOI] [PubMed] [Google Scholar]
  • 3.Yamashina A, Tomiyama H, Arai T. Brachial-ankle pulse wave velocity as a marker of atherosclerotic vascular damage and cardiovascular risk. Hypertens Res. 2003;26:615–622. doi: 10.1291/hypres.26.615. [DOI] [PubMed] [Google Scholar]
  • 4.Munakata M, Ito N, Nunokawa T, Yoshinaga K. Utility of automated brachial ankle pulse wave velocity measurements in hypertensive patients. Am J Hypertens. 2003;16:653–657. doi: 10.1016/s0895-7061(03)00918-x. [DOI] [PubMed] [Google Scholar]
  • 5.Imanishi R, Seto S, Toda G. High brachial-ankle pulse wave velocity is an independent predictor of the presence of coronary artery disease in men. Hypertens Res. 2004;27:71–78. doi: 10.1291/hypres.27.71. [DOI] [PubMed] [Google Scholar]
  • 6.Kubozono T, Miyata M, Ueyama K. Clinical significance and reproducibility of new arterial distensibility index. Circ J. 2007;71:89–94. doi: 10.1253/circj.71.89. [DOI] [PubMed] [Google Scholar]
  • 7.Yambe T, Yoshizawa M, Saijo Y. Brachio-ankle pulse wave velocity and cardio-ankle vascular index (CAVI) Biomed Pharmacother. 2004;58(Suppl 1):895–898. doi: 10.1016/s0753-3322(04)80015-5. [DOI] [PubMed] [Google Scholar]
  • 8.Shirai K, Utino J, Otsuka K, Takata M. A novel blood pressure-independent arterial wall stiffness parameter: Cardio-ankle vascular index (CAVI) J Atheroscler Thromb. 2006;13:101–107. doi: 10.5551/jat.13.101. [DOI] [PubMed] [Google Scholar]
  • 9.Hayashi K, Sato M, Niimi H. Analysis of the constitutive laws of the vascular wall by finite deformation theory [in Japanese] Iyodenshi To Seitai Kogaku. 1975;13:293–298. [PubMed] [Google Scholar]
  • 10.Kawasaki T, Takeuchi K, Hasegawa M. Noninvasive measurement of common carotid artery effect with echo phase tracking system. J Japanese College Angiol. 1982;22:241–248. [Google Scholar]
  • 11.Okura T, Watanabe S, Kurata M. Relationship between cardio-ankle vascular index (CAVI) and carotid atherosclerosis in patients with essential hypertension. Hypertens Res. 2007;30:335–340. doi: 10.1291/hypres.30.335. [DOI] [PubMed] [Google Scholar]
  • 12.Mizuguchi Y, Oishi Y, Tanaka H. Arterial stiffness is associated with left ventricular diastolic function in patients with cardiovascular risk factors: Early detection with the use of cardio-ankle vascular index and ultrasonic strain imaging. J Card Fail. 2007;13:744–751. doi: 10.1016/j.cardfail.2007.05.010. [DOI] [PubMed] [Google Scholar]
  • 13.Uchida H, Nakamura Y, Kaihara M. Practical efficacy of telmisartan for decreasing morning home blood pressure and pulse wave velocity in patients with mild-to-moderate hypertension [published correction appears in Hypertens Res. 2006;29:295] Hypertens Res. 2004;27:545–550. doi: 10.1291/hypres.27.545. [DOI] [PubMed] [Google Scholar]
  • 14.JATOS Study Group The Japanese Trial to Assess Optimal Systolic Blood Pressure in Elderly Hypertensive Patients (JATOS): Protocol, patient characteristics, and blood pressure during the first 12 months. Hypertens Res. 2005;28:513–520. doi: 10.1291/hypres.28.513. [DOI] [PubMed] [Google Scholar]
  • 15.Staessen JA, Fagard R, Thijs L, Systolic Hypertension in Europe (Syst-Eur) Trial Investigators Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet. 1997;350:757–764. doi: 10.1016/s0140-6736(97)05381-6. [DOI] [PubMed] [Google Scholar]
  • 16.Hansson L, Hedner T, Lund-Johansen P. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem (NORDIL) study. Lancet. 2000;356:359–365. doi: 10.1016/s0140-6736(00)02526-5. [DOI] [PubMed] [Google Scholar]
  • 17.Opie LH, Schall R. Evidence-based evaluation of calcium channel blockers for hypertension: Equality of mortality and cardiovascular risk relative to conventional therapy [published correction appears in J Am Coll Cardiol. 2002;39:1409-1410] J Am Coll Cardiol. 2002;39:315–322. doi: 10.1016/s0735-1097(01)01728-4. [DOI] [PubMed] [Google Scholar]
  • 18.Nissen SE, Tuzcu EM, Libby P, CAMELOT Investigators Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: The CAMELOT study: A randomized controlled trial. JAMA. 2004;292:2217–2225. doi: 10.1001/jama.292.18.2217. [DOI] [PubMed] [Google Scholar]
  • 19.Yoshii T, Iwai M, Li Z. Regression of atherosclerosis by amlodipine via anti-inflammatory and anti-oxidative stress actions. Hypertens Res. 2006;29:457–466. doi: 10.1291/hypres.29.457. [DOI] [PubMed] [Google Scholar]
  • 20.Nilsson J, Sjölund M, Palmberg L. The calcium antagonist nifedipine inhibits arterial smooth muscle cell proliferation. Atherosclerosis. 1985;58:109–122. doi: 10.1016/0021-9150(85)90059-0. [DOI] [PubMed] [Google Scholar]
  • 21.Ding Y, Vaziri ND. Nifedipine and diltiazem but not verapamil up-regulate endothelial nitric-oxide synthase expression. J Pharmacol Exp Ther. 2000;292:606–609. [PubMed] [Google Scholar]
  • 22.Hasegawa M. Fundamental research on human aortic pulse wave velocity. Jikei Med J. 1970;85:742–760. [Google Scholar]
  • 23.Cameron J. Estimation of arterial mechanics in clinical practice and as a research technique. Clin Exp Pharmacol Physiol. 1999;26:285–294. doi: 10.1046/j.1440-1681.1999.03032.x. [DOI] [PubMed] [Google Scholar]
  • 24.Benetos A, Adamopoulos C, Bureau JM. Determinants of accelerated progression of arterial stiffness in normotensive subjects and in treated hypertensive subjects over a 6-year period. Circulation. 2002;105:1202–1207. doi: 10.1161/hc1002.105135. [DOI] [PubMed] [Google Scholar]
  • 25.Brener SJ, Ivanc TB, Poliszczuk R. Anti hypertensive therapy and regression of coronary artery disease: Insights from the Comparison of Amlodipine versus Enalapril to Limit Occurrences of Thrombosis (CAMELOT) and Norvasc for Regression of Manifest Atherosclerotic Lesions by Intravascular Sonographic Evaluation (NORMALISE) trials. Ana Heart J. 2006;152:1059–1063. doi: 10.1016/j.ahj.2006.07.022. [DOI] [PubMed] [Google Scholar]
  • 26.Munakata M, Nagasaki A, Nunokawa T. Effects of valsartan and nifedipine coat-core on systemic arterial stiffness in hypertensive patients. Am J Hypertens. 2004;17:1050–1055. doi: 10.1016/j.amjhyper.2004.06.028. [DOI] [PubMed] [Google Scholar]
  • 27.Ichihara A, Hayashi M, Koura Y. Long-term effects of intensive blood-pressure lowering on arterial wall stiffness in hypertensive patients. Am J Hypertens. 2003;16:959–965. doi: 10.1016/s0895-7061(03)01004-5. [DOI] [PubMed] [Google Scholar]
  • 28.Vaziri ND, Xu ZG, Shahkarami A. Role of AT-1 receptor in regulation of vascular MCP-1, IL-6, PAI-l, MAP kinase, and matrix expressions in obesity. Kidney Int. 2005;68:2787–2793. doi: 10.1111/j.1523-1755.2005.00750.x. [DOI] [PubMed] [Google Scholar]
  • 29.Sasamura H, Kitamura Y, Nakamura M. Effects of the angiotensin receptor blocker candesartan on arterial stiffness and markers of extracellular matrix metabolism in patients with essential hypertension. Clin Exp Hypertens. 2006;28:511–520. doi: 10.1080/10641960600798721. [DOI] [PubMed] [Google Scholar]
  • 30.Yambe T, Meng X, Hou X. Cardio-ankle vascular index (CAVI) for the monitoring of the atherosclerosis after heart transplantation. Biomed Pharmacother. 2005;59(Suppl 1):S177–5179. doi: 10.1016/s0753-3322(05)80028-9. [DOI] [PubMed] [Google Scholar]
  • 31.Wakabayashi I, Masuda H. Association of acute-phase reactants with arterial stiffness in patients with type 2 diabetes mellitus. Clin Chim Acta. 2006;365:230–235. doi: 10.1016/j.cca.2005.08.023. [DOI] [PubMed] [Google Scholar]

Articles from Current Therapeutic Research, Clinical and Experimental are provided here courtesy of Elsevier

RESOURCES